Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Rectal Neoplasms 18Colorectal Neoplasms 16Breast Neoplasms 10Pancreatic Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 4Gallbladder Neoplasms 3Bile Duct Neoplasms 3Uterine Cervical Neoplasms 2Somatostatinoma 2Esophageal Neoplasms 2Anus Neoplasms 2Anal Canal Carcinoma 2Adenoma, Islet Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulinoma 1Inflammatory Breast Neoplasms 1Glucagonoma 1Gastro Oesophageal Cancer 1Gastrinoma 1Erythema Multiforme 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × Capecitabine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡